Leukocyte-poor platelet-rich plasma is more effective than the conventional therapy with acetaminophen for the treatment of early knee osteoarthritis
- 1.2k Downloads
Knee osteoarthritis (OA) is a degenerative and progressive articular cartilage disease. Infiltration of autologous platelet-rich plasma (PRP) has been proposed as a therapeutic alternative due to the content of biologically active cytokines in PRP. We aimed to compare the clinical response of acetaminophen and intra-articular leukocyte-poor PRP (LP-PRP) in early knee OA.
Materials and methods
A total of 65 patients with clinically and radiographically documented knee OA (grade 1–2) were analyzed. Patients were randomized into two groups: 32 were treated with acetaminophen (500 mg/8 h) over 6 weeks, and 33 received three intra-articular injections of autologous LP-PRP (once every 2 weeks). All patients were evaluated by the Visual Analogue Scale (VAS), the Western Ontario and McMaster Universities (WOMAC) score, and the SF-12 health survey at baseline and 6, 12, and 24 weeks of follow-up. All LP-PRP preparations were analyzed for the platelet, leukocyte, IL-1ra, and TGF-β concentrations.
The decrease in the VAS pain level in the LP-PRP group was greater than that in the acetaminophen group (p < 0.05). Patients treated with LP-PRP showed a sustained improvement in knee function at week 24 (p < 0.01). The SF-12 results only indicated an improvement in quality-of-life in the LP-PRP group at 6, 12, and 24 weeks of follow-up (p < 0.01). Both IL-1ra and TGF-β were detected in the LP-PRP samples (313.8 ± 231.6 and 21,183.8 ± 8556.3 pg/mL, respectively).
Treatment with LP-PRP injections resulted in a significantly better clinical outcome than did treatment with acetaminophen, with sustained lower EVA and WOMAC scores and improvement in quality-of-life (higher SF-12 score). Therapy with LP-PRP may positively modify the inflammatory joint environment by counteracting IL-1β action.
KeywordsLeukocyte-poor platelet-rich plasma Acetaminophen Osteoarthritis Intra-articular infiltration
M. Simental-Mendía received a fellowship from the Consejo Nacional de Ciencia y Tecnología (CONACYT), México.
Compliance with ethical standards
Conflict of interest
- 2.Nelson AE, Allen KD, Golightly YM et al (2014) A systematic review of recommendations and guidelines for the management of osteoarthritis: the chronic osteoarthritis management initiative of the US bone and joint initiative. Semin Arthritis Rheum 43:701–712. doi: 10.1016/j.semarthrit.2013.11.012 CrossRefPubMedGoogle Scholar
- 7.Zhang W, Nuki G, Moskowitz RW et al (2010) OARSI recommendations for the management of hip and knee osteoarthritis: Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil 18:476–499. doi: 10.1016/j.joca.2010.01.013 CrossRefPubMedGoogle Scholar
- 15.Pereira C, Scaranari M, Benelli R et al (2013) Dual effect of platelet lysate on human articular cartilage: a maintenance of chondrogenic potential and a transient pro-inflammatory activity followed by an inflammation resolution. Tissue Eng Part A 19:1476–1488. doi: 10.1089/ten.TEA.2012.0225 CrossRefPubMedGoogle Scholar
- 20.Hawker GA, Mian S, Kendzerska T, French M (2011) Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF. Arthritis Care Res (Hoboken) 63:S240–S252. doi: 10.1002/acr.20543 CrossRefGoogle Scholar
- 32.Kon E, Mandelbaum B, Buda R et al (2011) Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: from early degeneration to osteoarthritis. J Arthrosc Relat Surg 27:1490–1501. doi: 10.1016/j.arthro.2011.05.011 CrossRefGoogle Scholar
- 35.Sánchez M, Fiz N, Azofra J et al (2012) A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis. J Arthrosc Relat Surg 28:1070–1078. doi: 10.1016/j.arthro.2012.05.011 CrossRefGoogle Scholar
- 36.Vaquerizo V, Plasencia MA, Arribas I et al (2013) Comparison of intra-articular injections of plasma rich in growth factors (PRGF-Endoret) versus durolane hyaluronic acid in the treatment of patients with symptomatic osteoarthritis: a randomized controlled trial. J Arthrosc Relat Surg 29:1635–1643. doi: 10.1016/j.arthro.2013.07.264 CrossRefGoogle Scholar
- 41.AAOS (2013) Treatment of osteoarthritis of the knee evidence-based guideline, 2nd edn. Am Acad Orthop Surg, Board DirGoogle Scholar